# Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

> **NCT00748215** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Colorectal Cancer
- Diarrhea

## Interventions

- **DRUG:** calcium aluminosilicate anti-diarrheal
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00748215
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-04
- **Primary completion:** 2014-08-12
- **Final completion:** 2014-08-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748215, "Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00748215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*